Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17855408 | 0.97 | ALDH1A1 (0.32) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL21141186 | 0.97 | ALDH1A1 (0.32) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL17854312 | 0.96 | ALDH1A1 (0.32) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL25472932 | 0.96 | MAPT (0.33) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL25145820 | 0.95 | ALDH1A1 (0.31) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL25472906 | 0.95 | MAPT (0.33) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL17693362 | 0.95 | ALDH1A1 (0.31) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL17855076 | 0.93 | GPR3 (0.32) | ALDH1A1MAPTGPR3POLBTDP1 | |
| SCHEMBL17855422 | 0.93 | ALDH1A1 (0.31) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL17855417 | 0.93 | ALOX5 (0.33) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160181525-A1 | COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20160181525-A1 | COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160181525-A1 | COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | ESR1, ESR2, CCNE2 | ALDH1A1 848/4885MAPT 1923/4885HPGD 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.